Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.

Wu, Lixian

Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Feb 2015 - 833-43 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1557-3265

10.1158/1078-0432.CCR-13-3317 doi


Animals
Antineoplastic Agents--pharmacology
Cell Line, Tumor
Cell Proliferation--drug effects
Curcumin--analogs & derivatives
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl--antagonists & inhibitors
HSP90 Heat-Shock Proteins--antagonists & inhibitors
Humans
Imatinib Mesylate
Immunoblotting
Immunoprecipitation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--pathology
Mice
Mice, Inbred NOD
Mice, SCID
Neoplastic Stem Cells--drug effects
Xenograft Model Antitumor Assays